Go further with cancer screening

Introducing Galleri®, the first-of-its-kind multi-cancer early detection test that looks for a signal shared by 50+ types of cancer with a single blood test.¹

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

There are over 100 types of cancer, but only 5 have recommended screening tests.

Your clients deserve more.

Life Insurance Distribution One Pager

Learn more about Galleri in Life Insurance

GRAIL’s life insurance partners want to help people detect cancer early when treatment with curative intent may be possible.

“After we saw all the studies…we couldn’t find anything else where we could find as big of an impact on people’s lives.”

Marc Gigiuere, President & CEO
Munich RE Life U.S

“I think every company should be to doing this…it would be wonderful for our industry to be perceived as an industry that isn’t just there in death but helps people along the way.”

Brooks Tingle, President & CEO
John Hancock Insurance

“I can’t think of any other thing that we’ve ever done in our business or probably ever will do that is so meaningful and so personal to… a client. It’s really incredible.”

Carl Peterson, Managing Principal
Lindberg & Ripple | M Financial Group

galleri.com/life-insurance | LinkedIn | Facebook | Twitter

For marketing and distribution
support, please reach out to
lifedistribution@grailbio.com

For client questions, including
help ordering the Galleri
test, please reach out to
customerservice@grailbio.com
or 833-694-2553.

1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.Ann Oncol. 2021;32(9):1167-77. DOI: https://doi.org/10.1016/j.annonc.2021.05.806.